Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Joanna J. Regan is active.

Publication


Featured researches published by Joanna J. Regan.


The Journal of Pediatrics | 2015

No Visible Dental Staining in Children Treated with Doxycycline for Suspected Rocky Mountain Spotted Fever

Suzanne R. Todd; F. Scott Dahlgren; Marc S. Traeger; Eugenio D. Beltrán-Aguilar; Donald W. Marianos; Charlene Hamilton; Jennifer H. McQuiston; Joanna J. Regan

OBJECTIVE To evaluate whether cosmetically relevant dental effects occurred among children who had received doxycycline for treatment of suspected Rocky Mountain spotted fever (RMSF). STUDY DESIGN Children who lived on an American Indian reservation with high incidence of RMSF were classified as exposed or unexposed to doxycycline, based on medical and pharmacy record abstraction. Licensed, trained dentists examined each childs teeth and evaluated visible staining patterns and enamel hypoplasia. Objective tooth color was evaluated with a spectrophotometer. RESULTS Fifty-eight children who received an average of 1.8 courses of doxycycline before 8 years of age and who now had exposed permanent teeth erupted were compared with 213 children who had never received doxycycline. No tetracycline-like staining was observed in any of the exposed childrens teeth (0/58, 95% CI 0%-5%), and no significant difference in tooth shade (P=.20) or hypoplasia (P=1.0) was found between the 2 groups. CONCLUSIONS This study failed to demonstrate dental staining, enamel hypoplasia, or tooth color differences among children who received short-term courses of doxycycline at <8 years of age. Healthcare provider confidence in use of doxycycline for suspected RMSF in children may be improved by modifying the drugs label.


The Journal of Pediatrics | 2014

Self-reported treatment practices by healthcare providers could lead to death from Rocky Mountain spotted fever.

Jillian Zientek; F. Scott Dahlgren; Jennifer H. McQuiston; Joanna J. Regan

Among 2012 Docstyle survey respondents, 80% identified doxycycline as the appropriate treatment for Rocky Mountain spotted fever in patients ≥ 8 years old, but only 35% correctly chose doxycycline in patients <8 years old. These findings raise concerns about the higher pediatric case-fatality rate of Rocky Mountain spotted fever observed nationally. Targeted education efforts are needed.


Clinical Infectious Diseases | 2015

Risk Factors for Fatal Outcome From Rocky Mountain Spotted Fever in a Highly Endemic Area—Arizona, 2002–2011

Joanna J. Regan; Marc S. Traeger; Dwight Humpherys; Dianna L. Mahoney; Michelle Martinez; Ginny L. Emerson; Danielle M. Tack; Aimee Geissler; Seema Yasmin; Regina Lawson; Velda Williams; Charlene Hamilton; Craig Levy; Ken Komatsu; David A. Yost; Jennifer H. McQuiston

BACKGROUND Rocky Mountain spotted fever (RMSF) is a disease that now causes significant morbidity and mortality on several American Indian reservations in Arizona. Although the disease is treatable, reported RMSF case fatality rates from this region are high (7%) compared to the rest of the nation (<1%), suggesting a need to identify clinical points for intervention. METHODS The first 205 cases from this region were reviewed and fatal RMSF cases were compared to nonfatal cases to determine clinical risk factors for fatal outcome. RESULTS Doxycycline was initiated significantly later in fatal cases (median, day 7) than nonfatal cases (median, day 3), although both groups of case patients presented for care early (median, day 2). Multiple factors increased the risk of doxycycline delay and fatal outcome, such as early symptoms of nausea and diarrhea, history of alcoholism or chronic lung disease, and abnormal laboratory results such as elevated liver aminotransferases. Rash, history of tick bite, thrombocytopenia, and hyponatremia were often absent at initial presentation. CONCLUSIONS Earlier treatment with doxycycline can decrease morbidity and mortality from RMSF in this region. Recognition of risk factors associated with doxycycline delay and fatal outcome, such as early gastrointestinal symptoms and a history of alcoholism or chronic lung disease, may be useful in guiding early treatment decisions. Healthcare providers should have a low threshold for initiating doxycycline whenever treating febrile or potentially septic patients from tribal lands in Arizona, even if an alternative diagnosis seems more likely and classic findings of RMSF are absent.


Clinical Infectious Diseases | 2013

A Confirmed Ehrlichia ewingii Infection Likely Acquired Through Platelet Transfusion

Joanna J. Regan; James Matthias; Audrey Green-Murphy; Danielle Stanek; Marsha Bertholf; Bobbi S. Pritt; Lynne M. Sloan; Aubree J. Kelly; Joseph Singleton; Jennifer H. McQuiston; Susan N. Hocevar; John P. Whittle

Ehrlichiosis is a tick-borne disease that ranges in severity from asymptomatic infection to fatal sepsis. Ehrlichiosis acquired from transfusion of blood products has not been documented in the literature to date. A case of Ehrlichia ewingii infection likely transmitted by transfusion of leukoreduced platelets is described, and public health implications are discussed.


Clinical Infectious Diseases | 2015

Rocky Mountain Spotted Fever Characterization and Comparison to Similar Illnesses in a Highly Endemic Area—Arizona, 2002–2011

Marc S. Traeger; Joanna J. Regan; Dwight Humpherys; Dianna L. Mahoney; Michelle Martinez; Ginny L. Emerson; Danielle M. Tack; Aimee Geissler; Seema Yasmin; Regina Lawson; Charlene Hamilton; Velda Williams; Craig Levy; Kenneth Komatsu; Jennifer H. McQuiston; David A. Yost

BACKGROUND Rocky Mountain spotted fever (RMSF) has emerged as a significant cause of morbidity and mortality since 2002 on tribal lands in Arizona. The explosive nature of this outbreak and the recognition of an unexpected tick vector, Rhipicephalus sanguineus, prompted an investigation to characterize RMSF in this unique setting and compare RMSF cases to similar illnesses. METHODS We compared medical records of 205 patients with RMSF and 175 with non-RMSF illnesses that prompted RMSF testing during 2002-2011 from 2 Indian reservations in Arizona. RESULTS RMSF cases in Arizona occurred year-round and peaked later (July-September) than RMSF cases reported from other US regions. Cases were younger (median age, 11 years) and reported fever and rash less frequently, compared to cases from other US regions. Fever was present in 81% of cases but not significantly different from that in patients with non-RMSF illnesses. Classic laboratory abnormalities such as low sodium and platelet counts had small and subtle differences between cases and patients with non-RMSF illnesses. Imaging studies reflected the variability and complexity of the illness but proved unhelpful in clarifying the early diagnosis. CONCLUSIONS RMSF epidemiology in this region appears different than RMSF elsewhere in the United States. No specific pattern of signs, symptoms, or laboratory findings occurred with enough frequency to consistently differentiate RMSF from other illnesses. Due to the nonspecific and variable nature of RMSF presentations, clinicians in this region should aggressively treat febrile illnesses and sepsis with doxycycline for suspected RMSF.


American Journal of Tropical Medicine and Hygiene | 2014

Co-Infection of Rickettsia rickettsii and Streptococcus pyogenes: Is Fatal Rocky Mountain Spotted Fever Underdiagnosed?

Gregory Raczniak; Cecilia Y. Kato; Ida H. Chung; Amy L. Austin; Jennifer H. McQuiston; Erica Weis; Craig Levy; Maria da Gloria S. Carvalho; Audrey Mitchell; Adam Bjork; Joanna J. Regan

Rocky Mountain spotted fever, a tick-borne disease caused by Rickettsia rickettsii, is challenging to diagnose and rapidly fatal if not treated. We describe a decedent who was co-infected with group A β-hemolytic streptococcus and R. rickettsii. Fatal cases of Rocky Mountain spotted fever may be underreported because they present as difficult to diagnose co-infections.


Influenza and Other Respiratory Viruses | 2012

Epidemiology of influenza A (H1N1)pdm09‐associated deaths in the United States, September–October 2009

Joanna J. Regan; Ashley Fowlkes; Matthew Biggerstaff; Michael A. Jhung; Jacqueline Gindler; Erin D. Kennedy; Victoria Fields; Lyn Finelli

Please cite this paper as: Regan et al. (2012) Epidemiology of influenza A (H1N1)pdm09‐associated deaths in the United States, September–October 2009. Influenza and Other Respiratory Viruses 6(601), e169–e177.


Public Health Reports | 2016

Tracing Airline Travelers for a Public Health Investigation Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infection in the United States, 2014

Joanna J. Regan; M. Robynne Jungerman; Susan A. Lippold; Faith Washburn; Efrosini Roland; Tina Objio; Christopher Schembri; Reena Gulati; Paul J. Edelson; Francisco Alvarado-Ramy; Nicki Pesik; Nicole J. Cohen

Objective. CDC routinely conducts contact investigations involving travelers on commercial conveyances, such as aircrafts, cargo vessels, and cruise ships. Methods. The agency used established systems of communication and partnerships with other federal agencies to quickly provide accurate traveler contact information to states and jurisdictions to alert contacts of potential exposure to two travelers with Middle East Respiratory Syndrome Coronavirus (MERS-CoV) who had entered the United States on commercial flights in April and May 2014. Results. Applying the same process used to trace and notify travelers during routine investigations, such as those for tuberculosis or measles, CDC was able to notify most travelers of their potential exposure to MERS-CoV during the first few days of each investigation. Conclusion. To prevent the introduction and spread of newly emerging infectious diseases, travelers need to be located and contacted quickly.


American Journal of Tropical Medicine and Hygiene | 2015

Medical and Indirect Costs Associated with a Rocky Mountain Spotted Fever Epidemic in Arizona, 2002–2011

Naomi A. Drexler; Marc S. Traeger; Jennifer H. McQuiston; Velda Williams; Charlene Hamilton; Joanna J. Regan

Rocky Mountain spotted fever (RMSF) is an emerging public health issue on some American Indian reservations in Arizona. RMSF causes an acute febrile illness that, if untreated, can cause severe illness, permanent sequelae requiring lifelong medical support, and death. We describe costs associated with medical care, loss of productivity, and death among cases of RMSF on two American Indian reservations (estimated population 20,000) between 2002 and 2011. Acute medical costs totaled more than


Travel Medicine and Infectious Disease | 2017

Maritime illness and death reporting and public health response, United States, 2010–2014

Caroline E. Stamatakis; Marion E. Rice; Faith Washburn; Kristopher J. Krohn; Millicent Bannerman; Joanna J. Regan

1.3 million. This study further estimated

Collaboration


Dive into the Joanna J. Regan's collaboration.

Top Co-Authors

Avatar

Jennifer H. McQuiston

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Susan A. Lippold

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Faith Washburn

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Craig Levy

Arizona Game and Fish Department

View shared research outputs
Top Co-Authors

Avatar

Francisco Alvarado-Ramy

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Tina Objio

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Aimee Geissler

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Clive Brown

Centers for Disease Control and Prevention

View shared research outputs
Researchain Logo
Decentralizing Knowledge